Alibaba-Backed Moonshot AI Unveils Kimi K2.5 to Challenge China’s AI Rivals 
ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company 
ASML’s EUV Monopoly Powers the Global AI Chip Boom 
C3.ai in Merger Talks With Automation Anywhere as AI Software Industry Sees Consolidation 
LVMH Investors Watch Earnings Closely as Luxury Recovery Faces New Challenges 
Google Halts UK YouTube TV Measurement Service After Legal Action 
Meta Faces Lawsuit Over Alleged Approval of AI Chatbots Allowing Sexual Interactions With Minors 
First Abu Dhabi Bank Reports 22% Jump in Q4 Profit, Beats Market Expectations 
Advantest Shares Hit Record High on Strong AI-Driven Earnings and Nvidia Demand 
Woodside Energy Flags Lower 2026 Production Outlook Despite Strong Q4 Revenue Beat 
Anthropic Raises 2026 Revenue Outlook by 20% but Delays Path to Profitability 
NVIDIA, Microsoft, and Amazon Eye Massive OpenAI Investment Amid $100B Funding Push 
Boeing Posts Fourth-Quarter Profit on Jeppesen Sale Despite Ongoing Unit Losses 
Samsung Electronics Posts Record Q4 2025 Profit as AI Chip Demand Soars 
Elon Musk Reportedly Eyes June 2026 SpaceX IPO Timed With Planetary Alignment and Birthday 
Sam Altman Criticizes ICE Enforcement as Corporate Leaders Call for De-Escalation 
MENLO PARK, Calif., May 22, 2017 -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a leading gene therapy company advancing novel medicines to address unmet needs in serious rare and ocular diseases, announced today that Amber Salzman, Ph.D., president and chief executive officer, will present at the Jefferies Global Healthcare Conference.
| Event: | Jefferies Global Healthcare Conference |
| Date: | June 7, 2017 |
| Time: | 1:30 – 2:00 p.m. ET |
| Location: | New York, NY |
A live and replay video webcast of the presentation will be available from Adverum’s website at http://investors.adverum.com.
About Adverum Biotechnologies, Inc.
Adverum is a gene therapy company advancing novel medicines that can offer life-changing benefits to patients living with serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat wet age-related macular degeneration (wAMD) and rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, the Company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development. For more information please visit www.adverum.com.
Contacts for Adverum: Leone Patterson Chief Financial Officer Adverum Biotechnologies, Inc. 650-665-7222 [email protected] Tricia Truehart Vice President The Trout Group LLC 646-378-2953 [email protected]
